WEEKLY e-ALERT  [ PREMIUM EDITION ]
Pharma China (www.pharmachinaonline.com) is the most influential English media and source of business intelligence covering the Chinese pharmaceutical sector. Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most MNC pharma companies, leading CROs, investment banks, consulting firms active in China as well as relevant industry associations and government agencies.

Note: To view full text of free articles, you need to register as a basic member first and then log in. To view premium articles, you need to subscribe to Pharma China as a premium member. For more information or subscription, please contact info@pharmachinaonline.com. If you wish to unsubscribe from this e-Alert, please reply this e-mail with "Remove" in the subject line.
Editor´s Picks
Cancer in the Asia-Pacific, a CRO Perspective(7/13/2017 )  (Premium)
  As cancer rates increase in the Asia-Pacific region, and clinical trial capabilities grow in India and China, demand for research is on the rise, according to this outsourcing-pharma.com article by Flora Southey.
Fast-tracking the Introduction of New Drugs(7/13/2017 )  (Premium)
  CHINA is overhauling its drug registration system as a part of efforts to accelerate commercial production of new medications, especially those developed by start-up firms, according to this Shanghai Daily article by Ding Yining.
Branded Generics in the Emerging Markets(7/12/2017 )  (Premium)
  This PharmExec article by Renaud Savary who argues that, from an investment perspective, branded generics in select emerging markets can offer above-market returns. These investments, however, carry operational risks and sometimes exchange-rate exposure.
The Market
Chinese Retail Drug Sales Growth Flat in the First Half of 2017(7/14/2017 )  (Premium)
  The share of pharmaceutical retail sales in overall Chinese drug sales was 22.5% in the first half of 2017, which is on par with the same in first half of 2016, according to a recent data release by SMEI. The sales of retail pharmacy drug sales slowed somewhat to 8%, reaching CNY 181.3 billion in the period.
Industry News
CFDA Issues 2016 Annual Report for Biological Product Batch Release(7/14/2017 )  (Premium)
  The CFDA released its 2016 Annual Report for Biological Product Batch Release on July 4. According to the report, the agency released 3,949 batches of vaccines (equivalent to about 646 million doses), 4,025 batches of blood products (equivalent to about 59.3 million doses) and 836 batches of blood screening reagents (equivalent to about 878 million doses) in 2016.
BGI Genomics Launches IPO on Chi-Next(7/14/2017 )  (Premium)
  BGI Genomics has been listed on the Shenzhen Chi-Next exchange, China's NASDAQ-style board of growth enterprises, of the Shenzhen Stock Exchange. The shares began trading on July 14 under the code 300676.
Qiagen's Chinese Translational Medicine JV Raises CNY 175M(7/12/2017 )  (free)
  Qiagen Translational Medicine Research in Suzhou has completed a Series A financing for CNY 175 million ($25.7 million) with Chinese venture capital firm Qiming Venture Partners leading the round.
AstraZeneca Expands Australian Facility to Meet Growing Chinese Demands for Respiratory Medicines(7/12/2017 )  (Premium)
  AstraZeneca has committed an additional A$100m ($76.4m) to expand its manufacturing facility in Sydney Australia, citing growing demand for innovative respiratory medicines in China.
Performance of Most Domestically-listed Chinese Pharma Companies Continued to Grow in H1(7/12/2017 )  (Premium)
  By July 11, 91 A-share listed Chinese biopharmaceutical sector companies issued their performance guidance in the first half, according to Tonghuashun Data. 76 expected to see their performance rise in the period.
CDE Publicizes Batch 21 of Drug Applications To Be Granted Priority Review Status(7/11/2017 )  (Premium)
  The Center for Drug Evaluation (CDE) under the CFDA publicized on July 11 a new list of ten drug applications (by application number) (21th Batch) which are to be granted priority review status.
CFDA Approves Sanofi's Osteoarthritis Drug Synvisc-One(7/11/2017 )  (Premium)
  Sanofi announced that the CFDA has approved the marketing of its osteoarthritis drug Synvic-One in China. Synvisc-One (hylan G-F 20) is the only treatment that can give patients up to six months of osteoarthritis (OA) knee pain relief with a single injection.
HUYA Bioscience Establishes Strategic Partnership with Suzhou BioTOP(7/10/2017 )  (free)
  HUYA Bioscience International announced on July 10 a strategic collaboration agreement with Suzhou BioTOP which will focus on promoting the development of biomedical innovations from companies and research organizations in Suzhou BioBay.
General Health
NHFPC Issues Notice for Service Model Transformation of Pharmacy Affairs Management(7/13/2017 )  (Premium)
  The NHFPC issued a notice (2017#26) to call for pharmacy service model transformation of hospital pharmacy management as a part of the ongoing healthcare reform.
Product/R&D News
Snapshot of Domestically R&D and IND Filings of PD-1/PD-L1 New Drugs in China(7/14/2017 )  (Premium)
  By July 10, there are a total of 15 domestic PD-1/PD-L1 new drugs which have filed IND with the CFDA for clinical research. Among them, ten are PD-1 mAbs, four are PD-L1 mAbs and one is PD-L1 single domain antibody.
CDE-Accepted Drug Registration Applications Up in the First Half(7/12/2017 )  (Premium)
  CDE accepted 550 drug registration applications in June, up substantially compared with 419 in May and 274 in March, according to SMEI. This boosts the number of drug applications accepted by CDE to a total of 2,114, among which 321 are for new drugs, 213 are for generic drugs and 215 are for imported drugs.
CFDA Approves BeyondSpring's Second Global Plinabulin Trial in China(7/10/2017 )  (Premium)
  BeyondSpring announced on July 6 that the FDA has approved its Clinical Trial Applications (CTAs) to allow the initiation of two global Phase 2/3 trials for Plinabulin for the prevention of chemotherapy-induced neutropenia in China.
People in the News
Executive Movements(7/13/2017 )  (Premium)
  Recent Chinese pharma-related movements at companies including Sanpower/Dendreon, Guangdong Techpool Biopharma, Shanghai ChemPartner and Sanofi China.
CFDA Official Moves(7/13/2017 )  (Premium)
  The CFDA announced on July 11 the numerous new appointments, removals and transfers of senior officials.
© Wicon International GroupˇˇSupport by: www.heightow.com Home | Site map | Contact Us | Links